Non-coding RNA in drug resistance of gastric cancer

Table 3 Summary of miRNAs involved in multiple drug resistance in gastric cancer

Dysregula-tion	miRNA	Pathway/target	Corresponding drugs	Ref.
Up-regulated	miR-19a/b	MeCP2	5-Fu, DDP	[41]
	miR-20a/b	LRIG1, EGFR, Livin, PI3K/AKT, p65, CYLD, MAPK/ERK, Survivin, HIPK2, NFKBIB, NFƙB	5-Fu, ADR, DDP, VCR	[42-46]
	miR-363	FBW7, c-Myc, c-Jun, cyclin E	Docetaxel, DDP, 5-Fu	[47]
	miR-21	PTEN, TIMP3, PI3K/AKT	DOX, DDP, PTX, Trastuzumab	[48-52]
	miR-27a	HIF-1α, GST-π, LRP, TS, MDR1/P-gp, Bcl-2	OXA	[46,53]
	miR-135a	E2F1, P-gp, c-Myc, DAPK2, AP-2α, Bcl-2	OXA, ADR	[54,55]
Down-regulated	miR-23b-3p	MALAT1, ATG12, LC3-I, ATG3, HMGB2, LC3-II	VCR, DDP	[29,56]
	miR-34a	PI3K/AKT/MRP1, HOTAIR, Wnt/β-catenin, MET	DDP	[24,57]
	miR-495	MDR1, ABCB1	DDP, DOX, TAX	[58]
	miR1955p	ZNF139, P-gp, BCL-2, MRP1	5-Fu, OXA	[59]
	miR-30a	MDR1, P-gp, Snail, E-cadherin, N-cadherin, Vimentin	5-Fu, DDP	[60-62]
	miR-101	ANXA2, P-gp, VEGF-C	DDP, VCR	[64]
	miR-145	CD44, Sox2, Oct4, Nanog	5-Fu, DDP	[65]
	miR-129	P-gp, Caspase-3/9,	DDP	[66]
	miR-27b	UCA1, Bcl-2, Cleaved caspase-3, HIF1A, MDR1, CCNG1	ADR, DDP, 5-Fu	[28,67]
	miR-126	EZH2	VCR, ADR	[68]
	miR-16	Cyclin J, FUBP1, hNIS, Bcl-2	Lapatinib, ADR Trastuzumab	[69,70]
	miR-1284	EIF4A1, Jun, MMP12, Myc	VCR	[71]
	miR-107	Lin28, P-gp, c-Myc, cyclin D1, Bcl-2, CDK6, NF-kB, TOPOII, Cleaved caspase3/9	OXA, PTX, 5-Fu, DOX	[72,73]
	miR-508-5p	P53, ABCB1, ZNRD1	ADR, DDP, 5-Fu, VCR	[67]
	miR-218	SMO, mTOR	OXA, 5-Fu, ADR, DDP	[74,75]
	let-7b	Lin28/Lin28B, c-Myc	DDP, VCR, 5-Fu	[76]
	miR-103	Cav-1, P-gp	DOX, ADR	[73]
	miR-129-5p	ABCB1, ABCC5, ABCG1	VCR, DDP, ADR, 5-Fu	[77]
	miR-185	ARC, RUNX3	DOX, DDP	[78]
	miR874	ATG16L1, Autophagy	DDP	[79]

5-Fu: 5-fluorouracil; DDP: Cisplatin; VCR: Vincristine; ADR: Adriamycin; PTX: Paclitaxel; TAX: Taxol; DOX: Doxorubicin; OXA: Oxaliplatin; P-gp: P-glycoprotein.